


FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 427.047	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/937306	
INTERNATIONAL APPLICATION NO. PCT/FR00/00812		INTERNATIONAL FILING DATE March 31, 2000		PRIORITY DATE CLAIMED April 2, 1999	
TITLE OF INVENTION COMBINATION OF NO SYNTHASE INHIBITOR(S) AND METABOLIC ANTIOXIDANTS					
APPLICANT(S) FOR DO/EO/US AUGET et al					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: PCT/IB/332 					

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/937306		INTERNATIONAL APPLICATION NO. PCT/FR00/00812		ATTORNEY'S DOCKET NUMBER 427.047	
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
				\$1000.00	
				\$1000.00	
				\$1000.00	
				\$100.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	24 - 20 =	4	x \$18.00	\$ 72.00	
Independent claims	- 3 =		x \$80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1072.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$1072.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$1072.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40.00	
TOTAL FEES ENCLOSED =				\$1112.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1112.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2275</u> . A duplicate copy of this sheet is enclosed. d. <input checked="" type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Charles A. Muserlian Bierman, Muserlian and Lucas 600 Third Avenue New York, NY 10016					
				 SIGNATURE	
				Charles A. Muserlian NAME	
				19,683 REGISTRATION NUMBER	

Our Ref.: 427.047

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
Michel AUGUET et al : PCT Date: March 31, 2000
PCT/FR00/00812 :
Serial No.: :
Filed: Concurrently Herewith :
For: COMBINATION...ANTI- :
OXIDANT(S) :
600 Third Avenue
New York, NY 10016

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend this application as follows:

IN THE SPECIFICATION:

Page 1, before line 1, insert

--This application is a 371 of PCT/FR00/00812 filed March
31, 2000.--

IN THE CLAIMS:

Claim 1 (amended) A pharmaceutical composition containing,
as active ingredient, at least one NO synthase inhibitory substance
and at least one metabolic antioxidant substance possessing at
least two thiol groups and which intervene(s) in the redox status
of thiol groups, and optionally a pharmaceutically acceptable

support.

Claim 2 (amended) A pharmaceutical composition according to claim 1, containing, as active ingredient, a NO synthase inhibitory substance and a metabolic antioxidant substance.

Claim 3 (amended) A pharmaceutical composition of claim 1 wherein the NO synthase inhibitory substance and the metabolic antioxidant substance are in separated form.

Claim 4 (amended) A pharmaceutical composition of claim 1 wherein the metabolic antioxidant is selected from the group consisting of dithiothreitol, pyritinol, lipoic acid and its derivatives, the dimeric disulfide derivatives of penicillamine or N-acetylcysteine, and peptides comprising at least two cysteine residues.

Claim 5 (amended) A pharmaceutical composition of claim 1 wherein the NO synthase inhibitory substance and the metabolic antioxidant substance are in the form of a salt.

Claim 6 (amended) A pharmaceutical composition of claim 5, wherein the salt is formed from a derivative of the NO synthase inhibitory substance containing at least one basic group and a derivative of the metabolic antioxidant substance containing at least one acid group.

Claim 7 (amended) A pharmaceutical composition of claim 5 wherein the metabolic antioxidant is selected from the group consisting of lipoic acid or its derivatives, the dimeric disulfide derivatives of penicillamine or N-acetylcysteine and peptides containing at least two cysteine residues.

Claim 8 (amended) A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is selected from the group consisting of a compound of amino acid type, a compound of the guanidine isothioureia, nitro- and cyano-aryl, amino-pyridine, amino-pyrimidine, amidine, indazole and imidazole families.

Claim 9 (amended) A pharmaceutical composition of claim 8 wherein the NO synthase inhibitor of amino-acid type selected from the group consisting of is L-arginine, ornithine and lysine derivatives.

Claim 10 (amended) A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is selected from the group consisting of L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl) imidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, N-phenyl-2-

thiophenecarboximidamine, S-ethylisothiourea, S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline.

Claim 11 (amended) A pharmaceutical composition of claim 1 wherein the metabolic antioxidant is lipoic acid in racemic or enantiomeric form.

Claim 12 (amended) A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is a neuronal and/or inducible NO synthase inhibitor.

Cancel claims 13 to 24 and add the following claims.

--25. A method of treating pathologies in warm-blooded animals wherein nitrogen monoxide and redox status of the thiol groups are involved comprising administering to warm-blooded animals in need thereof a sufficient amount of a composition of claim 1 sufficient to treat said pathologies.

26. A method of treating a pathology selected from the group consisting of cardiovascular and cerebrovascular disorders, septic shock, radioactive irradiation, solar radiation, organ transplants, disorders of the central or peripheral nervous system and more particularly Parkinsons' disease, proliferative and inflammatory diseases, autoimmune and viral diseases, diabetes and its complications, autosomal genetic diseases and pathologies

characterized by a production or a dysfunction of nitrogen monoxide and/or involving the redox status of thiol groups in warm-blooded animals comprising administering to warm-blooded animals in need thereof a sufficient amount of a composition of claim 1 to treat said pathology.

Claim 27 (amended) The method of claim 26 wherein the pathology is selected from the group consisting of migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or hemorrhagic origin, ischemias and thromboses.

Claim 28 (amended) The method of claim 26 wherein the pathology is selected from the group consisting of migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or hemorrhagic origin, ischemias and thromboses, neurodegenerative diseases, and more particularly Parkinsons's disease, pain, cerebral or bone marrow traumas, addiction to opiates, alcohol and addictive substances, erective and reproductive disorders, cognitive disorders, encephalopathies, depression, anxiety, schizophrenia, epilepsy, sleeping disorders and eating disorders.

Claim 29 (amended) The method of claim 26 wherein the pathology is selected from the group consisting of migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or hemorrhagic origin, ischemias and thromboses, neurodegenerative diseases, and more particularly Parkinsons's disease, pain,

cerebral or bone marrow traumas, addiction to opiates, alcohol and addictive substances, erective and reproductive disorders, cognitive disorders, encephalopathies, depression, anxiety, schizophrenia, epilepsy, sleeping disorders and eating disorders, lupus, AIDS, parasitic and viral infections, diabetes and its complications including retinopathies, nephropathies and polyneuropathies, multiple sclerosis and myopathies.

Claim 30 (amended) The method of claim 26 wherein the pathology is selected from the group consisting of migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or hemorrhagic origin, ischemias and thromboses, neurodegenerative diseases, and more particularly Parkinsons's disease, pain, cerebral or bone marrow traumas, addiction to opiates, alcohol and addictive substances, erective and reproductive disorders, cognitive disorders, encephalopathies, depression, anxiety, schizophrenia, epilepsy, sleeping disorders and eating disorders, lupus, AIDS, parasitic and viral infections, diabetes and its complications including retinopathies, nephropathies and polyneuropathies, multiple sclerosis and myopathies, cancer, atherosclerosis, pulmonary hypertension, glomerulonephritis, portal hypertension, cataracts, psoriasis, arthrosis and rheumatoid arthritis, fibroses, amyloidoses and inflammations of the gastrointestinal system and the pulmonary system and airways.

Claim 31 (amended) The method of claim 25 wherein the NO

synthase inhibitor is selected from the group consisting of a compound of amino acid type and a compound of the guanidine, isothiurea, nitro- or cyano-aryl, amino-pyridine or amino-pyrimidine, amidine, indazole or imidazole families.

Claim 32 (amended) The method of claim 31 wherein the NO synthase inhibitor is selected from the group consisting of L-arginine, ornithine and lysine derivatives.

Claim 33 (amended) The method of claim 25 wherein NO synthase inhibitor is selected from the group consisting of L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl) imidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, N-phenyl-2-thiophenecarboximidamine, S-ethylisothiurea, S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline.

Claim 34 (amended) The method of claim 25 wherein the metabolic antioxidant is selected from the group consisting of dithiothreitol, pyritinol acid or its derivatives, the dimeric disulfide derivatives of penicillamine or N-acetylcysteine and peptides comprising at least two cysteine residues.


Claim 35 (amended) The method of claim 25 wherein the metabolic antioxidant is lipoic acid, in racemic or enantiomeric form.

Claim 36 (amended) The method of claim 25 wherein the NO synthase inhibitor is a neuronal and/or inducible NO synthase inhibitor.

REMARKS

The amendment is submitted to insert reference to the PCT application and to conform the claims to the American practice.

Respectfully submitted,
BIERMAN, MUSERLIAN AND LUCAS


Charles A. Muserlian, #19,683
Attorney for Applicant(s)
Tel. # (212) 661-8000

CAM:sd
Enclosure: Return Receipt Postcard

COMBINATION OF NO SYNTHASE INHIBITOR(S)
AND METABOLIC ANTIOXIDANT(S)

--This application is a 371 of PCT/FR00/00812 filed March 31, 2000.--

5 The invention relates to a pharmaceutical composition containing, as active ingredient, one or many substance(s) which interfere(s) with the synthesis of nitrogen monoxide by inhibition of NO synthase and one or many metabolic antioxidant(s) which intervene(s) in the redox status of thiol groups, and optionally a pharmaceutically acceptable support. The invention also relates to a product containing one or many NO synthase inhibitory substance(s) and one or many metabolic antioxidant(s) which intervene(s) in the redox status of thiol groups, as a combination product, in separated form, of these active ingredients.

10 A pharmaceutical composition and a product according to the invention are useful in the treatment of pathologies where nitrogen monoxide and the metabolism of antioxidants (such as vitamin E or glutathione) as well as the redox status of the thiol groups are involved, and in particular :

- 15 . cardiovascular and cerebrovascular disorders comprising, for example, migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or haemorrhagic origin, ischemias and thromboses ;
- . septic shock, radioactive irradiation, solar radiation, organ transplants ;
- . disorders of the central or peripheral nervous system such as, for example, neurodegenerative diseases where cerebral infarctions, senile dementia, including Alzheimer's disease, Huntington's chorea, Parkinson's disease, Creutzfeld-Jacob's
- 20 disease, prion diseases, amyotrophic lateral sclerosis, but also pain, cerebral or bone marrow traumas, addiction to opiates, alcohol and addictive substances, erectile and reproductive disorders, cognitive disorders, encephalopathies, depression, anxiety, schizophrenia, epilepsy, sleeping disorders, eating disorders (anorexia, bulimia, etc.) can be mentioned in particular ;
- 25 . proliferative and inflammatory diseases such as, for example, cancer, atherosclerosis, pulmonary hypertension, glomerulonephritis, portal hypertension, cataracts, psoriasis, arthrosis and rheumatoid arthritis, fibroses, amyloidoses, inflammations of the gastrointestinal system (colitis, Crohn's disease) or of the pulmonary system and airways (asthma, sinusitis) as well as contact or delayed
- 30 hypersensitivities ;

JC16 Rec'd PCT/PTO SEP 20 2001

5

10

15

20

25

8. ^{Claim 1, wherein} ~~Pharmaceutical composition according to one of the preceding claims, in which~~
the NO synthase inhibitor is a compound of amino acid type ~~or~~ a compound of the
guanidine, isothioureia, nitro- ^{and} ~~or~~ cyano-aryl, amino-pyridine, ~~or~~ amino-pyrimidine,
amidine, indazole ^{and} ~~or~~ imidazole families.

selected from the
group consisting of

5

A

A

20

25

30

~~16. Product according to claim 14, for the treatment of disorders of the central or peripheral nervous system such as neurodegenerative diseases, and more particularly Parkinson's disease, pain, cerebral or bone marrow traumas, addiction to opiates,~~

COMBINATION OF NO SYNTHASE INHIBITOR(S)
AND METABOLIC ANTIOXIDANT(S)

The invention relates to a pharmaceutical composition containing, as active ingredient, one or many substance(s) which interfere(s) with the synthesis of nitrogen monoxide by inhibition of NO synthase and one or many metabolic antioxidant(s) which intervene(s) in the redox status of thiol groups, and optionally a
5 pharmaceutically acceptable support. The invention also relates to a product containing one or many NO synthase inhibitory substance(s) and one or many metabolic antioxidant(s) which intervene(s) in the redox status of thiol groups, as a combination product, in separated form, of these active ingredients.

A pharmaceutical composition and a product according to the invention are useful in
10 the treatment of pathologies where nitrogen monoxide and the metabolism of antioxidants (such as vitamin E or glutathione) as well as the redox status of the thiol groups are involved, and in particular :

- . cardiovascular and cerebrovascular disorders comprising, for example, migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or haemorrhagic origin, ischemias and thromboses ;
15 . septic shock, radioactive irradiation, solar radiation, organ transplants ;
- . disorders of the central or peripheral nervous system such as, for example, neurodegenerative diseases where cerebral infarctions, senile dementia, including Alzheimer's disease, Huntington's chorea, Parkinson's disease, Creutzfeld-Jacob's
20 disease, prion diseases, amyotrophic lateral sclerosis, but also pain, cerebral or bone marrow traumas, addiction to opiates, alcohol and addictive substances, erectile and reproductive disorders, cognitive disorders, encephalopathies, depression, anxiety, schizophrenia, epilepsy, sleeping disorders, eating disorders (anorexia, bulimia, etc.) can be mentioned in particular ;
- 25 . proliferative and inflammatory diseases such as, for example, cancer, atherosclerosis, pulmonary hypertension, glomerulonephritis, portal hypertension, cataracts, psoriasis, arthrosis and rheumatoid arthritis, fibroses, amyloidoses, inflammations of the gastrointestinal system (colitis, Crohn's disease) or of the pulmonary system and airways (asthma, sinusitis) as well as contact or delayed
30 hypersensitivities ;

- . auto-immune and viral diseases such as lupus, AIDS, parasitic and viral infections, diabetes and its complications including retinopathies, nephropathies and polyneuropathies, multiple sclerosis, myopathies ;
- . autosomal genetic diseases such as Unverricht-Lundborg disease ;
- 5 . pathologies characterized by a production or a dysfunction of nitrogen monoxide and/or the metabolism of glutathione and of the redox status of thiol groups.

In all these pathologies, there is experimental evidence demonstrating the involvement of nitrogen monoxide or of a dysfunction of the metabolism of glutathione (Kerwin et al., Nitric oxide : a new paradigm for second messengers, J. Med. Chem. 38, 4343-4362, 1995 ; Packer et al., Alpha-lipoic acid as biological antioxidant, Free Radical Biology & Medicine 19, 227-250, 1995). This is the case in particular in Parkinson's disease which illustrates the invention (Beal MF, Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44[Suppl 1], S110-S114, 1998 ; Donato et al., Glutathione in Parkinson's disease :
10 a link between oxidative stress and mitochondrial damage. Ann. Neurol. 32, S111-S115, 1992). In this context, medicaments which can inhibit the formation of nitrogen monoxide and/or re-establish the biological functionality of the thiol groups or glutathione can have beneficial effects. As is shown in the experimental part, combining an NO synthase inhibitor and a metabolic antioxidant, active ingredients
15 acting with different mechanisms, increases the therapeutic effect of these active ingredients in unexpected fashion. This invention is particularly well illustrated in an experimental pathological model of Parkinson's disease : intoxication with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine).
20

A subject of the invention is therefore a pharmaceutical composition containing, as
25 active ingredient, one or many substance(s) which interfere(s) with the synthesis of nitrogen monoxide by inhibition of NO synthase and one or many metabolic antioxidant(s) possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, and optionally a pharmaceutically acceptable support.

A more particular subject of the invention is a pharmaceutical composition
30 containing, as active ingredient, a substance which interferes with the synthesis of nitrogen monoxide by inhibition of NO synthase and a metabolic antioxidant which intervenes in the redox status of thiol groups.

The term NO synthase inhibitor should be understood to mean any specific or non-specific inhibitor of one of its isoforms, either constitutive (neuronal or

endothelial) or inducible (Kerwin et al., Nitric oxide: a new paradigm for second messengers, J. Med. Chem. 38, 4343-4362, 1995). NO synthase inhibitors according to the invention can be chosen, for example, from certain amino acid derivatives such as L-arginine derivatives, guanidines, isothiouras, nitro- or cyano-aryls, amino-pyridines or amino-pyrimidines, amidines, indazoles or imidazoles as defined hereafter.

The term metabolic antioxidant substance which intervenes in the redox status of thiol groups should be understood to mean any chemical substance possessing at least two thiol groups capable of forming an intra or intermolecular disulphide bridge by oxidation, this substance being able to be found in reduced or oxidized form. Such compounds allow the chelation of divalent cations, the regeneration of antioxidants such as vitamin E or glutathione, and intervene in the redox status of thiol groups. The metabolic antioxidants according to the invention can be chosen, for example, from dithiothreitol, pyritinol, lipoic acid (Packer et al., Alpha-lipoic acid as biological antioxidant, Free Radical Biology & Medicine 19, 227-250, 1995) or its derivatives as defined hereafter, the dimeric disulphide derivatives of penicillamine or N-acetylcysteine, or also the peptides containing at least two cysteine residues. These substances can be natural or synthetic.

In a pharmaceutical composition according to the invention, the NO synthase inhibitor and metabolic antioxidant can be present in separated form or in combined form forming a salt. Of course, the formation of a salt is only envisaged if one of the active ingredients has an acid group and the other active ingredient a basic group. Preferably, the salt is formed from a derivative of the NO synthase inhibitory substance containing at least one basic group and a derivative of the metabolic antioxidant containing an acid group. Thus, the NO synthase inhibitor can be chosen, for example, from the compounds as defined hereafter. The metabolic antioxidant can be chosen, for example, from lipoic acid or its derivatives as defined hereafter, the dimeric disulphide derivatives of penicillamine or N-acetylcysteine.

A subject of the invention is also a product containing one or many NO synthase inhibitory substance(s) and one or many metabolic antioxidant substance(s) possessing at least two thiol groups, which intervene(s) in the redox status of thiol groups, as combination product, in separated form, for simultaneous or sequential use in the treatment of pathologies in which nitrogen monoxide and/or the redox status of thiol groups are involved, such as cardiovascular and cerebrovascular disorders, septic shock, radioactive irradiation, solar radiation, organ transplants, disorders of the central or peripheral nervous system and more particularly

Parkinson's disease, proliferative and inflammatory diseases, autoimmune and viral diseases, diabetes and its complications, autosomal genetic diseases and all the pathologies characterized by a production or a dysfunction of nitrogen monoxide and/or involving the redox status of thiol groups.

- 5 In a pharmaceutical composition or product according to the invention, the NO synthase inhibitor and the metabolic antioxidant can be present in doses which can be identical or different. The doses are chosen according to the compounds combined with appropriate diluents or excipients.

- 10 The NO synthase inhibitor and metabolic antioxidant can be administered in simultaneous or sequential manner, by the same administration route or by different routes, according to whether they are present in separated or combined form. Preferably, the administration routes are oral, parenteral or topical.

- 15 Among NO synthase inhibitors, compounds of amino-acid type, non amino-acid type and aromatic amine type can be defined. NO synthase inhibitors of amino-acid type can be compounds as described in the Applications WO 95/00505, WO 94/12163, WO 96/06076, WO 98/28257, or L-arginine, ornithine, or lysine derivatives as described in the Applications WO 93/24126, WO 95/01972, WO 95/24382, WO 95/09619 and WO 95/22968 (the amino acids are excluded from this class as they have no activity in the NO system ; L-arginine alone has an activity : this is the natural substrat of NO synthase).

NO synthase inhibitors of non amino-acid type can be compounds of the guanidine, isothiourrea, nitro- or cyano-aryl, amino-pyridine or amino-pyrimidine, amidine, indazole or imidazole families as well as substituted heterocycles or condensed piperidines.

- 25 NO synthase guanidine inhibitors can be compounds as defined in the Applications WO 95/28377, WO 91/04023, WO 94/21621, WO 96/18607 and WO 96/18608.


NO synthase isothiourrea inhibitors can be compounds as defined in the Applications WO 95/09619, WO 96/09286, WO 94/12165, WO 96/14842, WO 96/18607, WO 96/18608, WO 96/09286, EP 717040 and EP 718294.

- 30 NO synthase nitro- or cyano-aryl inhibitors can be compounds as defined in the Application WO 94/12163.

NO synthase amino-pyridine or amino-pyrimidine inhibitors can be compounds as defined in the Applications WO 94/14780, WO 96/18616, WO 96/18617, WO 98/45294, WO 98/24766, WO 00/02860, JP 98/001470, JP 98/120654 and JP 98/036351.


- 5 NO synthase amidine inhibitors can be compounds as defined in the Applications WO 95/11014, WO 96/01817, WO 95/05363, WO 95/11231, WO 96/14844, WO 96/19440, WO 98/42696, WO 98/58934, WO 98/50380, WO 98/50382, JP 98/265450, or compounds such as N-phenyl-2-thiophenecarboximidamide.

- 10 NO synthase indazole inhibitors can be compounds as defined in the Application WO 98/02442 or compounds of general formula I_A



in which R₁ represents one or more substituents chosen from a hydrogen atom, the nitro, halo, lower alkyl or lower alkoxy radical.

- 15 NO synthase imidazole inhibitors can be compounds of the general formula II_A



- in which R₂ and R₃ represent, independently, a hydrogen atom, halo, hydroxy, amino, alkyl or alkoxy radical, or R₂ and R₃ are linked together and form the phenyl radical condensed with the imidazole ring, the phenyl radical being optionally substituted by one or more substituents chosen from hydroxy, trifluoromethyl, halo, carboxy, lower alkyl, lower alkoxy or lower alkenyl radicals ; R₄ represents a hydrogen atom, a lower alkyl, amino, lower alkyl amino or phenyl radical, the phenyl radical being optionally substituted by one or more substituents chosen from hydroxy, trifluoromethyl, halo, carboxy, lower alkyl, lower alkoxy or lower alkenyl radicals ; R₅ represents the hydrogen atom, a lower alkyl, amino, lower alkyl amino radical.

As it is used here, the term lower with reference to the alkyl and alkoxy groups designates saturated aliphatic hydrocarbon groups, linear or branched, containing 1 to 6 carbons such as, for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, methoxy and ethoxy. With reference to the alkenyl groups, the term lower designates groups containing 2 to 6 carbon atoms and one or more double or triple bonds such as, for example, vinyl, allyl, propenyl, isopropenyl, pentenyl, butenyl, hexenyl, propenyl and butadienyl groups. The term halo designates chloro, bromo, iodo or fluoro.

The condensed piperidines can be compounds as defined in the Application EP 870763.

The substituted heterocycles can be compounds as defined in the Applications WO 98/50372, WO 98/42667, WO 98/46611, WO 99/05131, WO 99/01455, JP 98/182618.

Preferably, the NO synthase inhibitor is a compound of amino-acid type and more particularly L-arginine, ornithine or lysine derivatives, or a compound of the guanidine, isothioureia, nitro- or cyano-aryl, amino-pyridine or amino-pyridine, amidine, indazole or imidazole families.

The metabolic antioxidant can be chosen from dithiothreitol, pyritinol, the compounds as defined in the Application EP 381439, lipoic acid (in racemic or enantiomeric form) and its derivatives, the dimeric disulphide compounds of penicillamine or N-acetylcysteine, and the peptides comprising at least two cysteine residues. Preferably, the derivatives of lipoic acid are the compounds as defined in the Applications EP 855396, EP 236929, EP 869126, FR 2707983, WO 99/45922 and JP 94227979.

A more particular subject of the invention is a composition or a product as defined above, characterized in that the NO synthase inhibitor is chosen from L-nitro-arginine (LNA), L-nitro-arginine methyl ester (LNAME), L-N-monomethylarginine (LNMMA), aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl) imidazole (TRIM), 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, N-phenyl-2-thiophenecarboximidamide, 2-iminotetrahydropyrimidine, S-ethylisothioureia, S-methyl-L-thiocitrulline or S-ethyl-L-thiocitrulline.

A more particular subject of the invention is a composition or a product as defined above, characterized in that the metabolic antioxidant is lipoic acid, in racemic or enantiomeric form.

5 More preferably, a subject of the invention is also a composition or a product as defined above, characterised in that the NO synthase inhibitor is an inhibitor of the neuronal and/or inducible NO synthase.

10 NO synthase inhibitor compounds and metabolic antioxidants are commercially available or can be prepared by methods known to the person skilled in the art (or by analogy to the latter) (P. Hamley et al, Bioorganic and medicinal chemistry letters, Vol. 5 (15), 1573-1576 (1995) ; W. M. Moore et al, J. Med. Chem., 39, 669-672 (1996) ; E. P. Garvey et al., The Journal of Biological Chemistry, Vol.269 (43), 26669-26676 (1994)).

15 All the technical and scientific terms used in the present text have the meanings known to a person skilled in the art. Moreover, all patents (or patent applications) as well as other bibliographical references are incorporated by way of reference.

The following examples are presented to illustrate the above procedures and must in no case be considered as a limit to the scope of the invention.

EXPERIMENTAL PART :

Pharmacological study of the products of the invention

20 The activity of the compounds of the invention was evaluated *in vivo* on a model of neurotoxicity with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). The administration of MPTP produces a syndrome similar to Parkinson's disease resulting in a degeneration of the dopaminergic nigrostriatal neurons. This was observed in man, primates and mice [Langston JW and Ballard PA, Parkinson's
25 disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, N.Engl.J.Med. 309, 310 (1983) ; Burns RS et al., A primate model of parkinsonism : selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci. U.S.A. 80, 4546-4550 (1983), Heikkila, RE. et al., Dopaminergic neurotoxicity of 1-methyl-
30 4-phenyl-1,2,5,6- tetrahydropyridine in mice, Science, 224, 1451-1453 (1984)].

Mice (C57BL6) weighing 15-25 g are injected three times with 15-20 mg/kg of MPTP by intraperitoneal route at 2-hour intervals. The products are injected by oral

route 90 minutes before each injection of MPTP and 90 min after the last and 24 hours after the first injection of MPTP. The mice are sacrificed 24 hours after the last injection of MPTP. The striatum is removed and its dopamine level is measured by high-performance liquid chromatography coupled with electrochemical detection.

- 5 The effectiveness coefficient of the compounds is calculated according to the ratio : dopamine level of the product group + MPTP / dopamine level of the MPTP group only. A product for which the effectiveness coefficient is \geq to 1.5 is considered beneficial.

Let A be the NO synthase inhibitor and B the metabolic antioxidant.

10 **Example 1**

Compound AB, combination of the active ingredients A and B. Compound A : N-phenyl-2-thiophenecarboximidamine, powerful NO synthase inhibitor. Compound B : reduced form of lipoic acid, metabolic antioxidant.

Compound of Example 1 : 4 groups of animals are constituted as follows :

- 15 Group 1 : treated with MPTP.
Group 2 : treated with A (3 mg/kg) + MPTP.
Group 3 : treated with B (10 mg/kg) + MPTP.
Group 4 : treated with AB + MPTP.

Group No.	Dopamine level ng/mg of tissue	Effectiveness coefficient
1	3.24	-
2	3.77	1.16
3	3.81	1.17
4	5.21	1.60

- 20 The results show that the lipoic acid, in reduced form, used as metabolic antioxidant at the dose of 10 mg/kg is ineffective for protecting the animal against the fall in dopamine which occurs after injection of MPTP. The N-phenyl-2-thiophenecarboximidamine used as NO synthase inhibitor at the dose of 3 mg/kg is

also ineffective. In contrast, the combination of the two compounds proves effective in restoring the dopamine level of the animals subjected to the MPTP neurotoxicity.

Example 2

- Compound AB, combination of the active ingredients A and B. Compound A :
5 N^Gnitro-arginine, powerful inhibitor of constitutive and inducible NO synthases.
Compound B : reduced form of lipoic acid, metabolic antioxidant.

Compound of Example 2 : 4 groups of animals are constituted as follows :

- 10 Group 1 : treated with MPTP.
Group 2 : treated with A (3 mg/kg) + MPTP.
Group 3 : treated with B (10 mg/kg) + MPTP.
Group 4 : treated with AB + MPTP.

Group No.	Dopamine level ng/mg of tissue	Effectiveness coefficient
1	4.11	-
2	6.98	1.69
3	4.48	1.09
4	8.65	2.1

The N^Gnitro-arginine used as an inhibitor of NO synthases, effective at the dose of 3 mg/kg, has an increased effectiveness when it is combined with lipoic acid.

- 15 The experimental results of Examples 1 and 2 therefore show a potentializing effect,
even a synergy between the two types of compounds.

CLAIMS

1. Pharmaceutical composition containing, as active ingredient, one or many NO synthase inhibitory substance(s) and one or many metabolic antioxidant substance(s) possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, and optionally a pharmaceutically acceptable support.
5
2. Pharmaceutical composition according to claim 1, containing, as active ingredient, a NO synthase inhibitory substance and a metabolic antioxidant substance.
3. Pharmaceutical composition according to one of claims 1 to 2, characterized in that the NO synthase inhibitory substance and the metabolic antioxidant substance are in separated form.
10
4. Pharmaceutical composition according to one of claims 1 to 3, in which the metabolic antioxidant is dithiothreitol, pyritinol, lipoic acid or its derivatives, the dimeric disulphide derivatives of penicillamine or N-acetylcysteine, or the peptides comprising at least two cysteine residues.
- 15 5. Pharmaceutical composition according to one of claims 1 to 2, characterized in that the NO synthase inhibitory substance and the metabolic antioxidant substance are in the form of a salt.
6. Pharmaceutical composition according to claim 5, characterized in that the salt is formed from a derivative of the NO synthase inhibitory substance containing at least one basic group and a derivative of the metabolic antioxidant substance containing at least one acid group.
20
7. Pharmaceutical composition according to one of claims 5 to 6, in which the metabolic antioxidant is lipoic acid or its derivatives, the dimeric disulphide derivatives of penicillamine or N-acetylcysteine, or the peptides containing at least two cysteine residues.
25
8. Pharmaceutical composition according to one of the preceding claims, in which the NO synthase inhibitor is a compound of amino acid type or a compound of the guanidine, isothioureia, nitro- or cyano-aryl, amino-pyridine or amino-pyrimidine, amidine, indazole or imidazole families.

9. Pharmaceutical composition according to claim 8 in which the NO synthase inhibitor of amino-acid type is L-arginine, ornithine or lysine derivatives.

10. Pharmaceutical composition according to one of the preceding claims, in which the NO synthase inhibitor is chosen from L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl) imidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, N-phenyl-2-thiophenecarboximidamide, S-ethylisothiurea, S-methyl-L-thiocitrulline or S-ethyl-L-thiocitrulline.

11. Pharmaceutical composition according to one of the preceding claims, in which the metabolic antioxidant is lipoic acid in racemic or enantiomeric form.

12. Pharmaceutical composition according to one of the preceding claims, in which the NO synthase inhibitor is a neuronal and/or inducible NO synthase inhibitor.

13. Product containing one or many NO synthase inhibitory substance(s) and one or many metabolic antioxidant substance(s) possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, as combination product in separated form, for simultaneous or sequential use in the treatment of pathologies in which nitrogen monoxide and the redox status of thiol groups are involved.

14. Product according to claim 13 for the treatment of pathologies such as cardiovascular and cerebrovascular disorders, septic shock, radioactive irradiation, solar radiation, organ transplants, disorders of the central or peripheral nervous system and more particularly Parkinson's disease, proliferative and inflammatory diseases, autoimmune and viral diseases, diabetes and its complications, autosomal genetic diseases and all the pathologies characterized by a production or a dysfunction of nitrogen monoxide and/or involving the redox status of thiol groups.

15. Product according to claim 14, for the treatment of cerebrovascular and cardiovascular disorders such as migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or haemorrhagic origin, ischemias and thromboses.

16. Product according to claim 14, for the treatment of disorders of the central or peripheral nervous system such as neurodegenerative diseases, and more particularly Parkinson's disease, pain, cerebral or bone marrow traumas, addiction to opiates,

alcohol and addictive substances, erective and reproductive disorders, cognitive disorders, encephalopathies, depression, anxiety, schizophrenia, epilepsy, sleeping disorders, eating disorders.

5 17. Product according to claim 14, for the treatment of autoimmune and viral diseases such as lupus, AIDS, parasitic and viral infections, diabetes and its complications including retinopathies, nephropathies and polyneuropathies, multiple sclerosis, myopathies.

10 18. Product according to claim 14, for the treatment of proliferative and inflammatory diseases such as cancer, atherosclerosis, pulmonary hypertension, glomerulonephritis, portal hypertension, cataracts, psoriasis, arthrosis and rheumatoid arthritis, fibroses, amyloidoses, inflammations of the gastrointestinal system or the pulmonary system and airways.

15 19. Product according to one of claims 13 to 18, in which the NO synthase inhibitor is a compound of amino acid type or a compound of the guanidine, isothioureia, nitro- or cyano-aryl, amino-pyridine or amino-pyrimidine, amidine, indazole or imidazole families.

20 20. Product according to claim 19 in which the NO synthase inhibitor of amino-acid type is L-arginine, ornithine or lysine derivatives.

25 21. Product according to one of claims 13 to 20, in which the NO synthase inhibitor is chosen from L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl) imidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, N-phenyl-2-thiophenecarboximidamide, S-ethylisothioureia, S-methyl-L-thiocitrulline or S-ethyl-L-thiocitrulline.

30 22. Product according to one of claims 13 to 21, in which the metabolic antioxidant is dithiothreitol, pyritinol, acid or its derivatives, the dimeric disulphide derivatives of penicillamine or N-acetylcysteine, or peptides comprising at least two cysteine residues.

23. Product according to one of claims 13 to 22, in which the metabolic antioxidant is lipoic acid, in racemic or enantiomeric form.

24. Product according to one of claims 13 to 23, in which the NO synthase inhibitor is a neuronal and/or inducible NO synthase inhibitor.

FOUO 90E/CE60

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (8-96)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

☒ Declaration OR
Submitted
with Initial Filing ☐ Declaration
Submitted after
Initial Filing

Attorney Docket Number

First Named Inventor

M. AUGUET

COMPLETE IF KNOWN

Application Number

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ASSOCIATION OF NO-SYNTHASE INHIBITOR(S) AND METABOLIC ANTIOXIDANT(S)

(Title of the invention)

the specification of which

☐ is attached hereto
OR

☒ was filed on (MM/DD/YYYY)

03/31/2000

as United States Application Number or PCT International

Application Number

PCT/FR00/00812

and was amended on (MM/DD/YYYY)

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
99/04134	France	04/02/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

(Page 1 of 5)

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

(Janvier 1997)

Please type a plus sign (+) inside this box →



PTO/SB/01 (8-96)
Approved for use through 9/30/98. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number	Name	Registration Number
Charles A. Muserlian	19,683		
Jordan B. Bierman	18,629		
Donald C. Lucas	31,275		
Bierman, Muserlian and Lucas	18,818		

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.


Direct all correspondence to:

Name	Bierman, Muserlian & Lucas		
Address			
Address	600 Third Avenue		
City	NEW YORK	State	New York
Country	U.S.A.	Telephone	(212) 661-8000
		Fax	(212) 661-8002

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name	Michel	Middle Initial		Family Name	AUGUET	Suffix e.g. Jr.	
Inventor's Signature					Date	04 september 2001	
Residence: City	PALaiseau Fpx	State		Country	FRANCE	Citizenship	French
Post Office Address	29 rue de la Butte de Rheims						
Post Office Address							
City	PALaiseau	State		Zip	F-91120	Country	FRANCE

☒ Additional inventors are being named on supplemental sheet(s) attached hereto

Please type a plus sign (+) inside this box → +

PTO/SB/01 (8-96)
Approved for use through 9/30/98. CMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

DECLARATION	ADDITIONAL INVENTOR(S) Supplemental Sheet
--------------------	--

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Jeremiah	Middle Initial		Family Name	HARNETT	Suffix e.g. Jr.	
Inventor's Signature					Date	04/09/2001	
Residence: City	GIF-SUR-YVETTE	State	FR	Country	FRANCE	Citizenship	Irish
Post Office Address	32 allée de la Bergerie						
Post Office Address							
City	GIF-SUR-YVETTE	State		Zip	F-91190	Country	FRANCE

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Pierre-Etienne	Middle Initial		Family Name	CHABRIER de LASSAUNIERE	Suffix e.g. Jr.	
Inventor's Signature					Date	04-09 2001	
Residence: City	PARIS	State	FR	Country	FRANCE	Citizenship	French
Post Office Address	134 quai Louis Blériot						
Post Office Address							
City	PARIS	State		Zip	F-75016	Country	FRANCE

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix e.g. Jr.	
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name		Middle Initial		Family Name		Suffix e.g. Jr.	
Inventor's Signature					Date		
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	

☐ Additional inventors are being named on supplemental sheet(s) attached hereto



+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION			PRIORITY DATA (Supplemental Sheet)		
Additional foreign applications:					
Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
			<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Additional provisional applications:					
Application Number			Filing Date (MM/DD/YYYY)		
Additional U.S. applications:					
U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)		

[illegible]

